

Hitachi uses digital technology for creation of next-generation biopharmaceuticals

07 April 2021 | News

Hitachi and Axcelead have agreed to start joint development of solutions contributing on more efficient creation of next-generation biopharmaceuticals



Hitachi, Ltd. and Axcelead, Inc. have announced that they have agreed on a comprehensive collaborative partnership to develop solutions contributing on more efficient creation of next-generation biopharmaceuticals with digital technology and drug discovery platform.

Japanese firm Hitachi has also made investment to Drug Discovery Gateway Fund (DDG Fund) managed by Whiz Partners Inc. Axcelead is the flagship portfolio company of DDG Fund.

Through this collaboration, Hitachi and Axcelead will develop solutions that support the more efficient creation of next-generation biopharmaceuticals with digital technology and drug discovery platforms, and also support entities that participate in this field.

In addition, the both companies will jointly promote the development of specialized human resources who are familiar with the development and manufacturing of next-generation biopharmaceuticals.

Hitachi and Axcelead aim to contribute to improving QoL (Quality of Life) for human through medical innovation with next-generation biopharmaceuticals.